General Motors shook up the car industry this past week, saying it is aiming to stop selling gasoline-powered cars by 2035, much sooner than many on Wall Street would have predicted.
It is a sign that analysts and investors should be sharpening their pencils to figure out what is likely—and what is possible—for global electric-vehicle demand. The results of that number crunching will help to show whether the market has valued highflying EV stocks correctly and which, if any, still offer good value.
It isn’t an easy equation to solve. Auto makers express their goals—one indication of what might happen in the market—in different ways.
General Motors (ticker: GM) has its target for 2035. Tesla (TSLA) CEO Elon Musk has talked about selling 20 million EVs by 2030 and plans to increase its production volume at 50% a year for the foreseeable future.
Volkswagen (VOW. Germany) wants up to 25% of vehicle sales to come from battery-powered electric vehicles by 2030. And Toyota (TM) plans to sell 5.5 million electrified vehicles by 2030—a figure that includes hybrid electric cars as well as fuel-cell vehicles.
Barron’s added up the numbers in the publicly announced goals, aligning them by year and filling in some gaps. We calculate that, based on company comments, somewhere between 15 million and 20 million EVs will be sold a year by 2025. That implies an average annual growth rate of about 50% between last year and then. With that growth, EVs would account for roughly 15% to 20% of total light-vehicle sales.
Wedbush analyst Dan Ives qualifies as an electric-vehicle bull, but his estimate of EVs’ share of the market isn’t that high. “I am laser-focused on the skyrocketing EV demand out of China, Biden green initiatives, and [battery innovation] across the EV supply chain,” he tells Barron’s. “It looks like a golden age for EVs.”
Still, he is assuming EVs will win about 10% of the global market by 2025.
Focusing on China is a good idea. It’s the largest new-car market in the world and government incentives make buying an EV a “no brainer” for most consumers, according to Ives. Goldman Sachs analyst Fei Fang has predicted EVs will have 20% of the Chinese market by 2025.
RBC analyst Joseph Spak recently projected battery- and hybrid-electric vehicles could account for roughly 15% of new-car sales by 2025. That call was made back in December, before GM announced its aspiration to be all-electric by 2035.
Now Spak believes his projection could be too low. He did his own math to illustrate why.
“GM historically has had [about] 17% total U.S. market share,” he wrote in a recent research note. In December, he expected EVs to account for 40% of U.S. new-car sales by 2035. But for GM to go all-electric by then, assuming it keeps its historic 17% of the market, it would have to win 43% of U.S. EV sales, he said.
“The other way to interpret this [math] is that there could be upside to our 40% [battery electric] mix assumption,” added the analyst. That would be bullish for EV stocks, but he has a word of caution too. “A massive ramp in battery supply is needed to support this,” he said.
That gets at another important point for investors. There are many tertiary effects from faster EV penetration.
For one, as EVs take a bigger share of the market, they will start to get more of the capital the industry is willing to spend on product development. GM, for instance, is spending about half its capital over the next few years on EV and autonomous-driving technologies. By 2030, cars powered by internal combustion engines—ICE cars, in industry jargon—won’t look as attractive, relatively speaking, as those programs are drained of resources.
Electricity infrastructure is another critical issue. Right now oil and the refining industry essentially power cars. In the future, utilities and the electric grid will bear the burden.
The math needed to predict global electricity demand is harder, but higher EV penetration in 2025 would probably boost growth, now at roughly 3% a year, by a couple of percentage points. That seems manageable, but it means more investment in utilities.
The other side off the electricity equation is oil. Oil demand could fall slightly compared with 2019, a pre-pandemic year, if the world’s pool of EVs grows faster than expected. There are roughly 2 billion light vehicles on the road and nearly all take gasoline.
The next step in this math class is to value the EV sector. That isn’t easy either.
Given the growth and accelerating penetration, figures for 2025, when EV companies should be making real money, seem like a reasonable place to start. Apple (AAPL), the world’s most valuable company, trades for about 19 times estimated 2025 cash flow of about $120 billion.
Tesla is trading for about 65 times estimated 2025 cash flows. That is triple the figure for Apple, although if Musk’s goals are met, Tesla’s annual sales will go from more than 4 million vehicles to about 20 million over the next five years—between 2025 and 2030.
China’s NIO (NIO) is another highly valued EV stock. Analysts haven’t made public projections for its 2025 financials. But its shares trade for about 30 times estimated 2024 cash flow. According to analysts, NIO vehicle shipments are expected to go from roughly 345,000 to about 800,00 from 2025 to 2030. That is less growth than Tesla is looking to produce, but it still implies sales would more than double.
The 2025 valuation math can’t tell investors to buy or sell the stock, or the sector, but it does offer context about the coming golden age of EVs. Tesla stock is up about 21% year to date. NIO shares are up almost 19%. The S&P 500 is up about 2%.
Investors expect a lot. Morgan Stanley’s Adam Jonas pointed out that January EV sales in the U.S. were still less than 3% of the total, but he isn’t an EV bear. He rates Tesla stock at Buy and has a target of $880 for the stock-price target.
The ICE Age is ending. If the switch to EVs is rapid, valuations for manufacturers might not be unreasonable. The effects on other industries are just starting to be felt.
What a quarter-million dollars gets you in the western capital.
Alexandre de Betak and his wife are focusing on their most personal project yet.
As global demand for longevity treatments surges, Australia is fast becoming a player in this lucrative industry.
There was a time — not so long ago — when the idea of an indulgent spa day was simply about relaxing massages and therapeutic facials, followed by a five-star lunch and perhaps a dip in a mineral pool. But the health and wellness industry has evolved rapidly, bringing with it an explosion of cutting-edge treatments designed to slow ageing, boost vitality, and extend healthspan.
Cold-water plunge pools, infrared saunas, and float tanks have taken over as the staples of health spas, wellness centres, and high-end gyms. Even real estate developments are tapping into this trend. But now, high-tech longevity treatments — from cryotherapy and IV infusions to genetic testing and advanced cellular therapies — are taking the wellness scene in Australia to unprecedented levels.
A burgeoning market globally, the health and wellness industry is estimated to have been worth more than US$5.6 trillion in 2022. Projections suggest this figure will grow to a staggering $13 trillion by 2031, with Australia steadily catching up to the US and Europe, where longevity treatments are thriving. High-profile figures like Gwyneth Paltrow, Jennifer Aniston, Chris Hemsworth, and even Tom Brady are among the faces championing biohacking and experimental therapies, from stem cell infusions to blood transfusions.
The Rise of Longevity Clinics in Australia
One of the key players in Australia’s emerging longevity scene is Tristan Sternson, founder of Super Young. Sternson’s foray into the world of longevity treatments began as he approached 40 — a milestone that made him reflect on his health. As a former elite athlete, the transition from feeling invincible to feeling vulnerable led him to explore solutions that would help him reclaim vitality.

Initially frustrated by the lack of accessible health data locally, Sternson turned to overseas clinics for tests and treatments that painted a clearer picture of his biological needs. His experience inspired him to create Super Young, a Melbourne-based clinic offering evidence-based therapies tailored to individual needs. Services include cryotherapy, IV infusions, genetic testing, and biological age assessments. Memberships range from $85–$289 per week, while one-off tests start at $899.
Sternson emphasises the importance of personalised treatments. “I want people to start with the evidence side of it so they can really understand their own body and what treatments will work for them,” he says.
The Science of Longevity Medicine
Dr Karen Coates, an integrative medical doctor and a presenter for The Longevity Project at Gwinganna Lifestyle Retreat, echoes Sternson’s emphasis on personalisation. She explains that longevity isn’t just about living longer but about living better — optimising health today while securing vitality for the future.
“One-size-fits-all approaches don’t apply when it comes to longevity,” says Dr Coates. “It’s about understanding your body’s genetic makeup and adopting personalised strategies to support health and longevity.”
At Gwinganna’s four-night Longevity Project retreat, guests can undergo gene testing, biological age assessments, and learn strategies to bridge the gap between chronological and biological age. Packages for the retreat range from $2915 to $5460.
Biohacking for All Budgets
Not all longevity treatments come with hefty price tags. Health coach Camilla Thompson points out that simple lifestyle adjustments — like cold showers to stimulate circulation or adding Celtic sea salt to water for better hydration — can supplement advanced therapies.
While advanced treatments like stem cell and peptide therapies are yet to gain widespread regulatory approval in Australia, Sternson is optimistic about their future. He envisions a time when longevity centres will be as common as gyms, giving clients the tools to monitor and manage their health with precision.
“What I’d love to see is health insurance companies get on board,” Sternson adds. “If they can give discounts for safe driving based on car data, why not for healthy habits based on glucose monitoring or other health indicators?”
As Australia continues to embrace longevity medicine, it’s clear the industry is poised to reshape not just health and wellness but how Australians approach ageing itself.